Associate Editor, Ophthalmology Times
COPHy 2023: Weighing the merits of offering teprotumumab for all patients with thyroid eye disease
Pedro Fonseca, MD, Coimbra Hospital and University Centre, Portugal, and Andrew G. Lee, MD, Blanton Eye Institute, Houston Methodist, Texas, USA, discuss the various pros and cons of offering teprotumumab for all patients with thyroid eye disease.
CDC gives update on VIM-GES-CRPA outbreak associated with artificial tears
There have been 8 reported patients with vision loss as well as 4 reports of enucleation, or surgical removal of eyeball.
NovaBay Pharmaceuticals Inc. announces the launch of Avenova Eye Health Support oral supplement
Avenova Eye Health Support oral supplement aims to comfort dry eyes and support overall eye health.
Prevent blindness declares March as workplace wellness month
The month will help to bring awareness to eye safety in the workplace and keep eyes safe and protected on the job.
Apotex Corp. issues voluntary nationwide recall of brimonidine tartrate ophthalmic solution, 0.15%
The voluntary recall is being issued out of an “abundance of caution” due to cracks that have developed in some of the units caps of the bottles.
Prevent Blindness to hold 18th annual “Eyes on Capitol Hill” advocacy event
The event will bring together patients, care partners, allied personnel, and medical professionals to speak directly with their elected officials to discuss a variety of vision and eye health issues
FDA accepts NDA for priority review for ADX-2191 for treatment of rare retinal cancer
Primary vitreoretinal lymphoma is a rare, aggressive, and potentially fatal retinal cancer that is diagnosed in approximately 300 to 600 patients in the United States per year.
OKYO Pharma announces customs clearance of GMP packaged OK-101 drug to be used in phase 2 clinical trial for treating dry eye disease
The company is anticipating the first patient-first visit in Q1 2023 and is looking to release top-line data from the Phase 2 trial in Q4 2023.
Altos Biologics completes patient enrollment in global Phase 3 clinical trial of Eylea biosimilar in neovascular age-related macular degeneration
The Alteogen Inc. subsidiary company provided an update on its ALT-L9 biosimilar to compete with EYLEA
Skye Bioscience receives positive safety review of topical cannabinoid receptor type 1 agonist after second cohort of phase 1 study
SBI-100 Ophthalmic Emulsion is a synthetic cannabinoid derivative to treat glaucoma and ocular hypertension.
Notal Vision shares data on novel home OCT device
Data shows the Notal Vision Home OCT device can be used to manage wet age-related macular degeneration (AMD).
EnVision Summit 2023: Creating the perfect environment
Multiple attendees of this year's EnVision Summit share insights into what makes the EnVision Summit an enjoyable experience and a great place to learn.
EnVision Summit 2023: A collective insight into the talk
Multiple attendees of this year's EnVision Summit share insights into their presentations.
Aldeyra Therapeutics: FDA accepts NDA for dry eye treatment
According to the company, reproxalap is a small-molecule modulator of reactive aldehyde species that will be used for the treatment of the signs and symptoms of dry eye disease.
Glaucoma 360: History and insight to the future
Adrienne Graves, PhD, and Andrew Iwach, MD, co-founders of Glaucoma 360, share insights into the formation of the Glaucoma Research Foundation and what makes Glaucoma 360 such a unique conference.
Glaucoma 360: Glaucoma management lessons learned from a pandemic
Oluwatosin U. Smith, MD, provides some key takeaways from her Glaucoma 360 2023 presentation, "Glaucoma Management Lessons Learned from a Pandemic."
ML6710i photodynamic laser for use with VISUDYNE approved by the FDA
Bausch + Lomb and Modulight announce the photodynamic laser for use with photodynamic therapy was approved by the FDA for the treatment of patients with subfoveal choroidal neovascularization due to AMD.
HuidaGene Therapeutics gains FDA clearance for multinational clinical trial of investigational new drug
HG004 aims to be more effective than other AAV2 products in treatment of inherited retinal diseases caused by mutations in the RPE65 gene.
Vial partners with RecensMedical in phase 3 clinical trial
Vial will be supporting RecensMedical with the phase 3 clinical trial for its Ocu-Cool system.
IDEAYA announces darovasertib Phase 2 initiation in neoadjuvant and adjuvant uveal melanoma
The Phase 2 clinical trial will evaluate darovasertib as monotherapy in neo-adjuvant and adjuvant settings in primary, non-metastatic uveal melanoma (UM) patients.
ARVO announces recipients of 2023 Pfizer Ophthalmics Carl Camras Translational Research Award
The intent of the award is to recognize early-career researchers who have exhibited excellence in research, as well as their fundamental scientific discoveries, concepts and novel technologies which have led to, or have the promise of leading to, clinical application.
New EndoGlide technique in treatment for Fuchs’ dystrophy shows promise
After comparing two techniques of corneal transplant tissue preparation, research shows a newer, faster technique is safe and effective.
ARVO announces the winners of multiple awards
These awards will help to advance the winner’s work and research in their respective fields in retinal surgery and age-related macular degeneration (AMD).
ARVO announces 2023 recipient of Genentech Career Development Award for Underrepresented Minority Emerging Vision Scientists
The Genentech Award is intended to provide early-career underrepresented minority investigators with an opportunity to explore novel and innovative research project ideas.
Trefoil Therapeutics announces first patient dosed in phase 1 study of TTHX1114 for treatment of corneal epithelial defects
Topical formulation of TTHX1114 has potential to accelerate the healing of epithelial defects
ARVO announces winners of 2023 research fellowships
The ARVO Foundation Collaborative Research Fellowship is intended to promote international scientific interactions and innovative research.
2 Clarke Drive Cranbury, NJ 08512